Assess Efficacy and Safety of a Nasal Spray in Adults With Dry or Irritated Nose

Inclusion Criteria:

1. Male and female subjects ≥18 years of age;

2. Subjects must have ongoing nasal irritation or dryness at Visit 1 (Day -4);

3. Total Irritation Score (sum of all 12 symptom scores) must average at least 8 overthe three-day run-in period (Day -3 to -1) and must be at least 8 at Visit 2 (Day 0). (Individual symptom score range is 0 - 3; Total Irritation Score range is 0 - 36.)

4. Dry Nose Symptom Score must average at least 2 over the three-day run-in period andmust be at least 2 at Visit 2 (Day 0). (Dry nose symptom score range is 0 - 3.)

5. The score of at least two other symptoms beside dry nose must average at least 2over the three-day run-in period and must be at least 2 at Visit 2 (Day 0). (Eachsymptom score range is 0 - 3.)

6. Twenty-five percent of the included subjects must have ongoing nasal symptoms causedby indoor pollutants from fireplaces, candles, smoking, or cooking, verified byprincipal investigator;

7. Subjects are willing to refrain from using any medications and/or acts for relief ofnasal symptoms during the whole study from Day -4 to Day 7; except foracetaminophen, ibuprofen, or vitamins;

8. Subjects are willing and able to comply with the requirements of the study to usethe study product according to use instructions, complete the daily symptom andproduct diaries and questionnaire(s), and visit the test facility as instructed;

9. Subjects can read, understand, and sign an informed consent document after beingadvised of the nature of the study.

Exclusion Criteria:

1. Currently taking any over-the-counter and prescription systemic/topicalcorticosteroids, antibiotics, antihistamines, cromone, nonsteroidalanti-inflammatory drugs (NSAIDs), leukotriene antagonists or topical or systemicdecongestants within the two weeks prior to Visit 1;

2. Currently using other nasal sprays, nasal pumps, nasal irrigation/lavage devices, oroils, creams, or gels into the nose;

3. Women who are pregnant and/or breastfeeding or planning to become pregnant duringthe study and within 30 days after the last application of the study product;

4. Have a dermatologic, respiratory, or medical condition (e.g., asthma, pneumonia,laryngotracheobronchitis, sinusitis, etc.) which, in the opinion of the principalinvestigator, could interfere with the interpretation of study results at the timeof the screening visit (Day -4);

5. Have a positive medical history of any significant illness within the 2 weeks priorto the screening visit (Day -4), which, in the opinion of the principalinvestigator, could interfere with the interpretation of study results;

6. Have a known allergy to any food or personal care products;

7. Have any kind of immunodeficiency;

8. Have a history of sensitivity to products as related to the product being evaluated;

9. Positive Coronavirus disease (COVID-19) test during the month before the study orduring the study;

10. Self-reported history of anaphylaxis;

11. Confirmed diagnosis of urticaria or eczema;

12. Confirmed diagnosis of asthma that requires more than intermittent rescuebeta-agonist treatment, for example, before exercise;

13. Immunotherapy during the past two years or ongoing immunotherapy;

14. Recent nasal or sinus surgery within the last six months;

15. Use of other nasal spray, pump, continuous positive airway pressure machine, nasalirrigation/lavage device, internal nasal gel, or nasal oil within 2 weeks before thescreening visit (Day -4);

16. Presence of nasal polyposis and chronic sinusitis (assessed by the PI);

17. Nasal anatomic abnormality, e.g., severely deviated septum, congenital cleftlip/palate, nasal bleeding diathesis (assessed by the PI); and/or

18. Any clinically significant co-morbid condition, which, in PI's opinion, may affectthe subject's safety and/or participation in the study.